Depixus are pioneering the development of MAGNA, a novel genetic analysis technology for decoding the dynamic genome.
Depixus has raised $34.5M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
Depixus's investors include Bpifrance, Casdin Capital, EISMEA, Arix Bioscience, Lansdowne Partners.
Depixus is headquartered in Courbevoie, France.
Depixus are pioneering the development of MAGNA, a novel genetic analysis technology for decoding the dynamic genome.
Depixus is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Depixus — Funding & Investors." VCBacked, December 15, 2021, https://www.vcbacked.co/company/depixus. Accessed September 29, 2026.
VCBacked. (2021). Depixus — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/depixus
{{cite web |title=Depixus — Funding & Investors |url=https://www.vcbacked.co/company/depixus |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated